v3.26.3
Segment Information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Reporting [Line Items]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Revenue:        
Total revenue $ 17,778 $ 0 $ 21,382 $ 0
Less:        
Cost of goods sold 192 0 285 0
Total research and development expenses 106,102 101,950 306,967 320,873
Total selling, general and administrative expenses 37,485 35,484 107,279 97,104
Intangible asset amortization 750 0 1,500 0
Total operating expenses 144,529 137,434 416,031 417,977
Loss from operations (126,751) (137,434) (394,649) (417,977)
Gain on sale of priority review voucher, net 194,000 0 194,000 0
Segment interest and other income, net 2,877 10,532 14,775 33,986
Therapeutics Segment        
Less:        
External research and development expenses - TV programs, including cost sharing 43,574 35,157 122,457 119,209
Other research and development expenses, including small molecule programs 21,145 25,056 61,193 79,403
Personnel related research and development expenses 41,383 41,737 123,317 122,261
Total research and development expenses 106,102 101,950 306,967 320,873
Personnel related selling, general and administrative expenses 22,502 22,079 67,987 60,932
Other selling, general and administrative expenses 14,983 13,405 39,292 36,172
Total selling, general and administrative expenses 37,485 35,484 107,279 97,104
Total operating expenses 144,529 137,434 416,031 417,977
Loss from operations (126,751) (137,434) (394,649) (417,977)
Gain on sale of priority review voucher, net 194,000 0 194,000 0
Segment interest and other income, net 2,877 10,532 14,775 33,986
Loss before income taxes $ 70,126 $ (126,902) $ (185,874) $ (383,991)